Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-06-07
2005-06-07
Spector, Lorraine (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S300000, C530S350000, C530S402000, C530S387300, C530S388220, C435S069100, C435S325000, C536S023100, C536S023500
Reexamination Certificate
active
06902910
ABSTRACT:
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 2003/0036168 (2003-02-01), Ni et al.
patent: 2003/0073187 (2003-04-01), Ni et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 401 384 (1996-03-01), None
patent: 0 857 782 (1998-08-01), None
patent: WO 91/06570 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
Chinnaiyan, A.M., et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science24:990-992 (Nov. 8, 1996).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Crit. Rev. Thera. Drug Carrier Sys.9:249-304, CRC Press, Inc. (1992).
Delgado, C., et al., “Quantitative analysis of polyethylene glycol (PEG) in PEG- modified proteins/cytokines by aqueous two-phase systems,”J. Biochem. Biophys. Methods29:237-250 (1994).
Dillman, R.O., “Monoclonal Antibodies for Treating Cancer,”Ann. Internal Med.111:592-603, American College of Physicians (1989).
Goodman, J.W., “Immunogens & Antigens,” in:Basic&Clin. Immunol., Stites, et al., eds., Appleton & Lange, Norwalk, CT, pp. 50-57 (1988).
Huston, J.S., et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,”Methods Enzymol.203:46-88, Academic Press, Inc. (1991).
Lerner, R.A., “Antibodies of Predetermined Specificity in Biology and Medicine,”Adv. Immunol.36:1-44, Academic Press, Inc. (1984).
Morpurgo, M., et al., “Covalent Modification of Mushroom Tyrosinase with Different Amphiphic Polymers for Pharmaceutical and Biocatalysis Applications,”App. Biochem. Biotechnol.56:59-72, Humana Press (1996).
Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,”Science229:1202-1207, American Association for the Advancement of Science (1985).
Pan, G., et al., “The Receptor for the Cytotoxic Ligand TRAIL,”Science276:111-113, American Association for the Advancement of Science (Apr. 4, 1997).
Roguska, M.A., et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,”Proc. Natl. Acad. Sci. USA91:969-973, National Academy of Sciences (1994).
Ruf, M., and Kössel, H., “Structure and expression of the gene coding for the α- subunit of DNA-dependent RNA polymerase from the chloroplast genome ofZea mays,”Nucl. Acids Res.16:5741-5754, IRL Press (1988).
Wiley, S.R., et al., “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis,”Immunity3:673-682, (1995).
EMBL Database, Accession No. AA100865, from Hillier, L., et al., (1996).
NCBI Entrez, GenBank Report, Accession No. W65310, from Hillier, L., et al., (May 1996).
NCBI Entrez, Accession No. AA102383, from Hillier, L., et al., (Oct. 1997).
NCBI Entrez, Accession No. AA102745, from Hillier, L., et al., (Nov. 1996).
NCBI Entrez, Accession No. AA102746, from Hillier, L., et al., (Nov. 1996).
NCBI Entrez, Accession No. AA150849, from Hillier, L., et al., (Dec. 1996).
NCBI Entrez, Accession No. U90875, from Pan, G., et al., (Apr. 18, 1997).
Pending Non-Provisional U.S. Appl. No. 09/912,292, filed Jul. 26, 2001, Not Published: pp. 1-75 (pp. 1 + 2 partially redacted); portion of Table 2; and SEQ ID NOs: 7950 and 52011.
Pending Non-Provisional U.S. Appl. No. 10/226,296, Ni et al., filed Aug. 23, 2002 (Not Published).
Pending Non-Provisional U.S. Appl. No. 10/226,318, Ni et al., filed Aug. 23, 2002 (Not Published).
NCBI Entrez, GenBank Report, Accession No. AA639619, Strausberg, R., National Center for Biotechnology Information (Oct. 1997).
Strader, C.D., et al., “Structural basis of β-adrenergic receptor function,”FASEB J.3:1825-1832, (1989).
Walczak, H., et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,”EMBO J.16:5386-5397, (1997).
Chantry, D., “Tumour necrosis factor antagonists,”Emerging Drugs4:5-13, Ashley Publications Ltd (1999).
Kim, K., et al., “Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal cancer cells,”Proceedings of the American Association for Cancer Research Annual Meeting40:486, 90thAnnual Meeting of the American Association for Cancer Research (Apr. 1999).
Marsters, S.A., et. al., “Control of Apoptosis Signaling by Apo2 Ligand,”Recent Progress in Hormone Research54:225-234, The Endocrine Society (1999).
International Search Report for International Application No. PCT/US 98/01464, European Patent Office, Netherlands, mailed on Jun. 17, 1998.
Supplementary Partial European Search Report for European Application No. EP 00 93 2061, European Patent Office, Netherlands, completed on Aug. 23, 2004.
Dixit Vishva M.
Gentz Reiner L.
Ni Jian
Pan James G.
Rosen Craig A.
Human Genome Sciences Inc.
Kaufman Claire M.
Spector Lorraine
Sterne Kessler Goldstein & Fox P.L.L.C.
The Regent of the University of Michigan
LandOfFree
Death domain containing receptor 4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Death domain containing receptor 4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death domain containing receptor 4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493715